Takeda's Edarbi Joins Busy Hypertension Field With Comparative Data

Takeda Pharmaceutical Company Ltd. secured FDA approval of a new angiotensin II receptor blocker Edarbi (azilsartan) for high blood pressure Feb. 25, but launching an anti-hypertensive in a crowded and highly genericized market will be challenging.